Evidence map›Paper›PMID 35259529›Full record

Trial reportClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2022

Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study.

Niklas Broman, Thijs Feuth, Tytti Vuorinen, Mika Valtonen, Ulla Hohenthal, Eliisa Löyttyniemi, Tiina Hirvioja, Päivi Jalava-Karvinen, Harri Marttila, Marika Nordberg and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 5 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Review
  12. Review
  13. Article
  14. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023
    Article
  15. Review
  16. Article
  17. 'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' - Author's reply.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Niklas BromanDepartment of Infectious Diseases, Turku University Hospital, Turku, Finland; University of Turku, Turku, Finland.
Thijs FeuthDivision of Medicine, Department of Pulmonary Diseases, Turku University Hospital, Turku, Finland; Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland.
Tytti VuorinenInstitute of Biomedicine, University of Turku, Turku, Finland; Department of Clinical Microbiology, Turku University Hospital, Turku, Finland.
Mika ValtonenDepartment of Anaesthesia and Intensive Care, Turku University Hospital, Turku, Finland.
Ulla HohenthalDepartment of Infectious Diseases, Turku University Hospital, Turku, Finland; University of Turku, Turku, Finland.
Eliisa LöyttyniemiDepartment of Biostatistics, University of Turku, Finland.
Tiina HirviojaDepartment of Infectious Diseases, Turku University Hospital, Turku, Finland; University of Turku, Turku, Finland.
Päivi Jalava-KarvinenDepartment of Infectious Diseases, Turku University Hospital, Turku, Finland; University of Turku, Turku, Finland.
Harri MarttilaDepartment of Hospital Hygiene and Infection Control, Turku University Hospital, Turku, Finland.
Marika NordbergÅland Central Hospital, Mariehamn, Åland, Finland.
Jarmo OksiDepartment of Infectious Diseases, Turku University Hospital, Turku, Finland; University of Turku, Turku, Finland. Electronic address: jarmo.oksi@utu.fi.
Turku University Hospital · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSevere COVID-19 is associated with an imbalanced immune response. We hypothesized that patients with enhanced inflammation, as demonstrated by increased levels of certain inflammatory biomarkers, would benefit from interleukin-6 blockage.

methodsPatients hospitalized with COVID-19, hypoxemia, and at least two of four markedly elevated markers of inflammation (interleukin-6, C-reactive protein, ferritin, and/or D-dimer) were randomized for tocilizumab (TCZ) plus standard of care (SoC) or SoC alone. The primary endpoint was clinical status at day 28 assessed using a seven-category ordinal scale, and the secondary endpoints included intensive care unit admission, respiratory support, and duration of hospital admission.

resultsClinical status at day 28 was significantly better in patients who received TCZ in addition to SoC compared with those who received SoC alone (p = 0.037). By then, 93% of patients who received TCZ (n = 53 of 57) and 86% of control patients (n = 25 of 29) had been discharged from the hospital. In addition, 47% of TCZ patients (n = 27 of 57) and 24% of control patients (n = 7 of 29) had resumed normal daily activities. The median length of hospitalization was 9 days (interquartile range, 7-12) in the TCZ group and 12 days (interquartile range, 9-15) in the control group (p = 0.014). DISCUSSION: In patients hospitalized with COVID-19, hypoxemia, and elevated inflammation markers, administration of TCZ in addition to SoC was associated with significantly better clinical recovery by day 28 and a shorter hospitalization compared with SoC alone.

Indexed as

COVID-19 Drug TreatmentAntibodies, Monoclonal, HumanizedBiomarkersHumansHypoxiaInflammationInterleukin-6Prospective StudiesSARS-CoV-2Treatment OutcomeAntibodies, Monoclonal, HumanizedBiomarkersInterleukin-6tocilizumabCOVID-19HospitalizationInterleukin-6SARS-CoV-2Tocilizumab

Identifiers

PMID35259529
PMCPMC8897958
OpenAlexW4220939720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.